GT Biopharma (GTBP) Shares Outstanding (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Shares Outstanding (Entity) of $35.2 million for Q1 2026, up 1287.08% year-over-year from $2.5 million in Q1 2025, and up 538.13% quarter-over-quarter from $5.5 million in Q4 2025.
GT Biopharma (GTBP) Shares Outstanding (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Shares Outstanding (Entity) for 17 consecutive years, with $35.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 1287.08% year-over-year to $35.2 million; the TTM figure through Mar 2026 stood at $35.2 million (up 1287.08% YoY), while the FY2025 annual figure was $5.5 million, up 146.75% from the prior year.
- Shares Outstanding (Entity) advanced to $35.2 million in Q1 2026 per GTBP's latest filing, from $5.5 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $35.2 million in Q1 2026 and bottomed at $1.0 million in Q2 2022.
- Historically, Shares Outstanding (Entity) has averaged $4.0 million across 5 years, with a median of $1.4 million in 2023.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) grew 6.55% — and 2026, when it jumped 1287.08%.
- GT Biopharma's Shares Outstanding (Entity) stood at $1.1 million in 2022, then grew by 26.62% to $1.4 million in 2023, then soared by 61.79% to $2.2 million in 2024, then jumped by 146.75% to $5.5 million in 2025, then surged by 538.13% to $35.2 million in 2026.
- Business Quant data shows GTBP's Shares Outstanding (Entity) at $35.2 million in Q1 2026, $5.5 million in Q4 2025, and $3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | 30.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.28 Mn |
| Dec 31, 2025 | 5.51 Mn |
| Sep 30, 2025 | 3.94 Mn |
| Jun 30, 2025 | 2.77 Mn |
| Mar 31, 2025 | 2.35 Mn |
| Dec 31, 2024 | 1.90 Mn |
| Sep 30, 2024 | 2.23 Mn |
| Jun 30, 2024 | 1.71 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Dec 31, 2023 | 1.35 Mn |
| Sep 30, 2023 | 1.37 Mn |
| Jun 30, 2023 | 1.34 Mn |
| Mar 31, 2023 | 1.30 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | 1.05 Mn |
| Jun 30, 2022 | 1.04 Mn |
| Mar 31, 2022 | 1.08 Mn |
| Dec 31, 2021 | 938,427.00 |
| Sep 30, 2021 | 1.05 Mn |
| Jun 30, 2021 | 1.12 Mn |